Apr 30, 2013, 04.43 PM | Source: PTI
Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.
The company has received the approval from the US Food and Drug Administration (USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.
The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said. Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added. Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.
Aurobindo Pharm stock price
On April 29, 2016, Aurobindo Pharma closed at Rs 760.95, down Rs 3.7, or 0.48 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 582.00.
The company's trailing 12-month (TTM) EPS was at Rs 26.47 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 28.75. The latest book value of the company is Rs 94.48 per share. At current value, the price-to-book value of the company is 8.05.
Ashish Kyal of wavesstrategy.com recommends sellin
The company has received final approval from the U
Krish Subramamnyam of Altamount Capital is of the
"The company has received final approval from the
Aurobindo Pharma has received final approval from
Aurobindo Pharma has entered the big league of Ind
The drugmaker, based in the southern Indian city o
"The formulations facility of the company at Panel